Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Optimization of Antimicrobial Photodynamic Therapy in Biofilms by Inhibiting Efflux Pump

Texto completo
Autor(es):
Fogaca de Aguiar Coletti, Tatiana Maria Starck ; de Freitas, Laura Marise ; Fusco Almeida, Ana Marisa ; Fontana, Carla Raquel
Número total de Autores: 4
Tipo de documento: Artigo Científico
Fonte: Photomedicine and Laser Surgery; v. 35, n. 7, p. 378-385, JUL 2017.
Citações Web of Science: 5
Resumo

Background: One of the main mechanisms of microbial resistance is given by efflux pumps, which reduce the effectiveness of antimicrobials by decreasing their intracellular concentration. Objective and methods: Considering that efflux pump inhibitors are promising adjuvant molecules for antibiotics in infections, in this study, using XTT test and colony forming unit (CFU) counting, we evaluated the association between the pump inhibitor verapamil (VP) and the antimicrobial photodynamic therapy (aPDT) mediated by methylene blue (MB) in biofilms of Escherichia coli and Staphylococcus aureus to optimize the bacterial reduction. Results: By applying 44J/cm(2), 215g/mL of VP, and 200g/mL of MB, we obtained 80% of metabolism reduction and 3.4 log(10) CFU/mL decrease for E. coli. Biofilm of S. aureus presented 80% of metabolism reduction and 3.65 log(10) CFU/mL decrease when 22J/cm(2), 312g/mL of VP, and 200g/mL of MB was used. Applying 200g/mL of MB, the E. coli biofilm required a higher dose of light, while the S. aureus biofilm required a higher concentration of VP to obtain the same reduction. Conclusions: The VP optimized the efficiency of aPDT and showed no toxicity when used alone in both strains, proving that inhibiting efflux pumps in combination with aPDT has great potential for clinical application. (AU)

Processo FAPESP: 16/05345-4 - Otimização da terapia fotodinâmica para doenças infecciosas utilizando o peptídeo aureína 1.2
Beneficiário:Carla Raquel Fontana
Modalidade de apoio: Auxílio à Pesquisa - Regular